Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance and strategic growth opportunities, particularly with FILSPARI's expanding market presence and potential FSGS approval. The Q&A section reinforced confidence in the company's strategies and market positioning, with positive insights on FILSPARI's growth potential and FDA interactions. Despite some uncertainties in FDA requests and specific metrics, the overall sentiment remains positive due to robust market opportunities and strategic plans.
Key Financial Performance
FILSPARI Net Product Sales (Q4 2025) $103.3 million, representing a 144% year-over-year growth. The growth was driven by strong demand, growing physician adoption, and increasing confidence in FILSPARI's role as a foundational therapy in IgA nephropathy.
FILSPARI Net Product Sales (Full Year 2025) $322 million, representing a 144% year-over-year growth. The increase was attributed to robust demand, a differentiated product profile, and simplification of REMS monitoring requirements.
Thiola and Thiola EC Net Product Sales (Q4 2025) $23.3 million. No year-over-year change or reasons for change were mentioned.
Thiola and Thiola EC Net Product Sales (Full Year 2025) $88.5 million. No year-over-year change or reasons for change were mentioned.
Total Net Product Sales (Q4 2025) $126.6 million. No specific year-over-year change or reasons for change were mentioned.
Total Net Product Sales (Full Year 2025) $410.5 million. No specific year-over-year change or reasons for change were mentioned.
License and Collaboration Revenue (Q4 2025) $3.1 million. No year-over-year change or reasons for change were mentioned.
License and Collaboration Revenue (Full Year 2025) $80.3 million. No year-over-year change or reasons for change were mentioned.
Research and Development Expenses (Q4 2025) $57.9 million, a decrease from $62.1 million in Q4 2024. The decrease was due to focused investment in key priorities.
Selling, General and Administrative Expenses (Q4 2025) $101.7 million, an increase from $69.5 million in Q4 2024. The increase was primarily due to investments in preparation for a potential FSGS launch, expanded sales force, and increased amortization expenses related to FILSPARI royalties.
Net Income (Q4 2025) $2.7 million, compared to a net loss of $60.3 million in Q4 2024. The improvement was driven by strong product sales and milestone payments.
Non-GAAP Adjusted Net Income (Q4 2025) $33.3 million, compared to a net loss of $39 million in Q4 2024. The improvement was attributed to strong product sales and milestone payments.
Cash, Cash Equivalents, and Marketable Securities (End of 2025) $322.8 million. This balance reflects proceeds from a $40 million milestone payment and $10 million from the Renalys acquisition by Chugai.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FILSPARI for IgA nephropathy: Record demand and strong revenue growth in Q4 2025. Physician confidence in FILSPARI is growing due to real-world experience and clinical data. FILSPARI is positioned as a foundational non-immunosuppressive therapy for chronic use.
FILSPARI for FSGS: sNDA accepted for FSGS indication. FDA PDUFA target action date set for April 13, 2026. FILSPARI shows potential to be the first approved medicine for FSGS, with strong data from Phase II and III trials.
Pegtibatinase for classical homocystinuria (HCU): Resumed site activation for pivotal Phase III HARMONY study. Pegtibatinase is positioned as a potential first disease-modifying therapy for HCU, addressing the underlying cause of the disease.
FILSPARI market expansion: FILSPARI generated $103 million in Q4 2025 and $322 million for the full year, representing 144% year-over-year growth. Broad utilization across adult IgA nephropathy patients, with increasing adoption in patients with lower proteinuria levels.
Commercial readiness for FSGS: Expanded sales force and commercial infrastructure in preparation for potential FSGS approval. Existing relationships and experience in IgA nephropathy position the company well for rapid uptake in FSGS.
Financial performance: Net product sales of $410.5 million in 2025, with $126.6 million in Q4. Strong cash position of $322.8 million as of December 31, 2025. No near-term need for additional capital.
Strategic focus: Priorities include solidifying FILSPARI's role in IgA nephropathy, delivering the first approved medicine for FSGS, advancing the HARMONY study for pegtibatinase, and building a durable rare disease company.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA approval delay for FILSPARI in FSGS: The FDA's major amendment to the sNDA for FILSPARI in FSGS has shifted the PDUFA target action date to April 13, 2026, delaying potential approval and market entry. This could impact revenue growth and strategic plans.
Competitive pressures in IgA nephropathy: Despite strong growth, additional therapies entering the market could challenge FILSPARI's market share and revenue potential in IgA nephropathy.
Regulatory and clinical trial risks for pegtibatinase: The resumption of site activation for the Phase III HARMONY study introduces risks related to enrollment, trial execution, and potential delays in bringing pegtibatinase to market.
Increased operating expenses: Higher SG&A expenses due to investments in FSGS launch preparation, expanded sales force, and commercial efforts for FILSPARI could strain financial resources.
Economic uncertainties: Potential economic challenges could affect patient access, reimbursement rates, and overall demand for therapies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FILSPARI in IgA Nephropathy: The company expects continued growth in 2026 and beyond, driven by increasing physician confidence, real-world experience, and strong execution in access, fulfillment, and patient support. FILSPARI is positioned as a foundational non-immunosuppressive therapy for chronic use and combination therapy.
FILSPARI in FSGS: The FDA PDUFA target action date for the sNDA is April 13, 2026. If approved, FILSPARI would be the first FDA-approved medication for FSGS. The company is prepared for commercial execution and anticipates a significant opportunity with rapid uptake in this indication.
Pegtibatinase for Classical Homocystinuria (HCU): The company has resumed site activation for the Phase III HARMONY study globally. Pegtibatinase is expected to be the first disease-modifying therapy for HCU, addressing the underlying cause of the disease. The study will evaluate sustained total homocysteine control and patient outcomes, with dosing of new patients expected to reinitiate soon.
Financial Outlook for 2026: The company anticipates meaningful net product sales growth from FILSPARI in IgA nephropathy, supported by strong demand and foundational therapy positioning. If approved for FSGS, this indication is expected to further drive top-line growth. Operating expenses are expected to grow moderately, driven by the Phase III HARMONY study and commercial investments for a potential FSGS launch.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide more details on the IgAN performance, including where the product is being prescribed and any payer issues?
A:The demand in Q4 was driven by the modification of REMS requirements, KDIGO publication, and broader community education. Most utilization is in the community, reflecting the patient population. FILSPARI has a strong position in payer formularies, with over 96% of the patient population having a pathway to reimbursement. New and repeat prescribers are contributing to growth, and trends for strong demand continued into the first part of the year.
Q:Have there been significant data requests from the FDA following the last disclosure, and how does the ALIGN IgAN study data compare to FILSPARI?
A:The FDA is engaged in reviewing the file, and the company has provided all requested information. FILSPARI was studied for 2 years against a max dose active comparator, showing a 3.7 ml greater absolute preservation in eGFR at 2 years. The ALIGN trial studied atrasentan against a placebo for 2.5 years, but cross-trial comparisons are not possible due to different designs. FILSPARI demonstrated superior long-term nephroprotection.
Q:Can you elaborate on the clinical benefit characterization for the FILSPARI sNDA and the proportion of new 4Q PSFs from patients with proteinuria less than 1.5 g/g?
A:The FDA's information requests late last year focused on clinical benefit. The company believes proteinuria can be used as a validated surrogate endpoint for full approval. More patient start forms are being received with proteinuria levels below 1.5 g/g, and the median is well below 1.5, but no specific percentages were provided.
Q:What is the sales infrastructure for IgAN, and how will it need to expand for FSGS approval?
A:The prescriber base for FSGS overlaps over 80% with IgAN. The field team has been expanded from about 80 to more than 100 personnel to optimize opportunities for both IgAN and FSGS.
Q:How should we expect gross-to-net to evolve over the year?
A:Gross-to-net discounts are expected to be highest in Q1 and lessen in Q2 and Q3. For the full year, gross-to-net percentages for FILSPARI are expected to be in the mid-20s, up from around 20% last year.
Q:What is the confidence level in getting FILSPARI approval for FSGS, and how is Otsuka's APRIL blocker launch impacting FILSPARI?
A:The company is confident in FILSPARI's profile for FSGS, supported by data and analyses. Otsuka's APRIL blocker launch reflects market growth, with no signs of switching or sequencing before FILSPARI. The market is expected to grow with combination therapies and novel treatments.
Q:How penetrated is the U.S. market for FILSPARI, and what is its growth potential?
A:FILSPARI has not yet reached 10% of the addressable patient population. The market has substantial growth potential, with opportunities to replace generic RAS inhibitors, expand treatment to untreated patients, and increase combination therapies. FILSPARI's peak potential for IgAN alone is well above $1 billion.
Q:What are the plans for communicating with the investor community as the FSGS PDUFA date approaches?
A:The company will enter a quiet period at the end of the month and provide updates after receiving material communication from the FDA.
Q:What are the expectations for new patient starts in Q1, and what is the latest on the FSGS label?
A:Q1 demand is strong, but variability may occur quarter-over-quarter. Label negotiations for FSGS have not yet started, but the company expects broad applicability for FILSPARI across all forms of FSGS.
Q:Will there be a halo effect for IgAN if FILSPARI is approved for FSGS?
A:Yes, a halo effect is expected due to the overlapping prescriber base, which could increase confidence in FILSPARI's profile for IgAN.
Q:Have there been consistent interactions with the FDA regarding the FSGS filing?
A:There have been recent changes within the review team, but continuity remains, especially with division-level leadership involved throughout the process.
Q:Why was there a lag between the growth in start forms and revenue in Q4?
A:There is always a time lag between patient start form generation and revenue recognition. December was the strongest month, and gross-to-net discounts were higher in Q4.
Q:What is the expected reduction in homocysteine levels for the pegtibatinase study, and are responder analyses being conducted?
A:The study is well-powered to achieve statistical significance, with prior studies showing a 67% reduction in total homocysteine. Responder analyses will look at clinically meaningful thresholds, and all patients have shown reductions in total homocysteine.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the FDA's information requests for the FILSPARI sNDA and the exact proportion of new patient start forms with proteinuria levels below 1.5 g/g. They also did not quantify the potential halo effect of FSGS approval on IgAN or provide specifics on the expected reduction in homocysteine levels for the pegtibatinase study.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CBS enzyme
Dr Chief
ENSEMBLE
FDA medication
FILSPARI ability
FILSPARI investment
FILSPARI potential
FILSPARI role
FSGS community
Nivi
Pegtibatinase
ability IgA
acquisition Chugai
action
adoption
advancement
agency review
balance sheet
combination therapy
conviction
day
deficiency
diet
discipline
effort FILSPARI
expense
extension study
feedback FSGS
flexibility
homocysteine
homocystinuria HCU
medicine community
pegtibatinase homocystinuria
position
potential treatment
record demand
role therapy
screening
site
support
term kidney
trial
week
TVTX Transcript
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Travere Therapeutics, Inc. (TVTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call demonstrates a strong potential for growth with the anticipated rapid uptake of FILSPARI in FSGS, supported by existing payer access and high unmet needs. The management's confidence in broad coverage and high compliance rates for FILSPARI in IgAN further bolster this sentiment. Despite some lack of specific guidance on numbers, the overall outlook is positive with strong demand drivers and physician acceptance. The Q&A section reinforces the positive sentiment with a focus on education and alignment with treatment guidelines.
Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call highlights strong financial performance and strategic growth opportunities, particularly with FILSPARI's expanding market presence and potential FSGS approval. The Q&A section reinforced confidence in the company's strategies and market positioning, with positive insights on FILSPARI's growth potential and FDA interactions. Despite some uncertainties in FDA requests and specific metrics, the overall sentiment remains positive due to robust market opportunities and strategic plans.
TVTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
